EVerZom, a pioneering biotechnology firm based in France, has secured €10 million in a Series A funding round to propel the clinical development of its first therapeutic candidate and further scale its exosome biomanufacturing platform. The investment, which brings together major players like Capital Grand Est, the European Innovation Council (EIC) Fund, Sorbonne Venture by Audacia, and Aloe Private Equity, will enable the company to initiate clinical trials for EVerGel™ in 2026 and expand its regenerative medicine pipeline.
This financing marks a critical juncture for EVerZom, which is positioning itself as a key player in the rapidly emerging field of exosome-based therapies. These nanoscopic particles, naturally secreted by cells, have shown immense potential in treating a range of inflammatory diseases, particularly those with significant unmet medical needs. By combining cutting-edge biomanufacturing techniques with innovative biomaterial formulations, EVerZom aims to offer new hope to patients suffering from debilitating conditions like Crohn’s disease.
In a statement, Jeanne Volatron, Co-Founder and CEO of EVerZom, highlighted the importance of this funding for the company’s future. “With this funding, we are taking a decisive step toward bringing the therapeutic potential of exosomes to patients in dire need of effective treatments. We are committed to developing solutions for diseases that severely impair quality of life, and our priority is to demonstrate the clinical efficacy of EVerGel™ in treating complex perianal fistulas associated with Crohn’s disease.”
The Promise of Exosome-Based Therapies
Exosomes, once considered a biological curiosity, have attracted significant attention in the pharmaceutical industry for their unique properties as natural mediators of intercellular communication. As vehicles capable of delivering genetic material, proteins, and other therapeutic molecules, exosomes are seen as a powerful tool in the treatment of diseases that involve immune or inflammatory dysfunctions.
At the heart of EVerZom’s innovation is EVerGel™, its first clinical candidate, which has demonstrated impressive preclinical results. Designed to treat complex perianal fistulas in patients with Crohn’s disease, EVerGel™ combines mesenchymal stem cell-derived exosomes with a biocompatible hydrogel. This combination not only enhances the therapeutic potency of the exosomes but also ensures prolonged local retention at the site of the disease, promoting faster and more complete healing. In animal models, EVerGel™ showed a healing rate of 87.5% within four weeks, compared to just 12.5% for the control group.
For the 2 million people globally suffering from Crohn’s disease, particularly those facing perianal fistulas, this development represents a critical new treatment option. The market gap in this area is underscored by the recent withdrawal of Alofisel, a stem cell-based treatment from Takeda, which failed in U.S. clinical trials in 2024. With over 60% of patients lacking an effective alternative, EVerZom sees a significant opportunity to bring a new, promising solution to market.
Strategic Expansion and Industrialization
Beyond its lead program, EVerZom is diversifying its pipeline to target other serious inflammatory diseases. Its next big preclinical candidate, Eviv, aims to tackle Acute-on-Chronic Liver Failure (ACLF), a condition with few treatment options outside of transplantation. By leveraging its exosome-based platform, EVerZom envisions providing solutions for a range of other therapeutic areas, including dermatology, cosmetics, and even veterinary care.
To support these efforts, the company is also focusing on scaling its bioproduction platform. EVerZom aims to industrialize its production capabilities, with plans to scale up to 50 liters of exosome product by 2026. This ambitious goal is made possible in part by a €3 million grant from the France 2030 initiative, awarded earlier this year. With its GMP-compliant production system, EVerZom is positioning itself to support both its clinical trials and eventual commercialization efforts.
“We are committed to building an industrial platform that not only supports the development of our own products but also enables partnerships with other pharmaceutical companies interested in exosome-based therapies,” said Volatron.
A Strong Position in a Growing Market
The future of exosome-based therapies looks increasingly bright, and EVerZom’s strategy positions it at the forefront of this field. With the backing of high-profile investors like the EIC Fund, which aims to support disruptive technologies, EVerZom has the resources to scale its platform and execute its clinical plans.
What sets EVerZom apart from competitors is its integrated approach, combining advanced exosome production techniques with proprietary formulations that improve the therapeutic efficacy and retention of these particles at the disease site. The company’s ability to industrialize exosome production while simultaneously advancing clinical trials gives it a significant edge in the fast-moving biotech landscape.
As the biotech industry continues to evolve, the race to develop next-generation therapies will likely accelerate. Exosome-based treatments, with their broad range of applications and natural origin, represent a promising frontier. EVerZom’s early success in demonstrating the potential of exosomes in complex diseases like Crohn’s disease positions it as a key player in what could become a multi-billion-dollar market.
Conclusion: A New Therapeutic Paradigm on the Horizon
If EVerZom successfully navigates the upcoming clinical trials and scales its technology, it has the potential to redefine the treatment landscape for inflammatory diseases. By harnessing the natural power of exosomes, the company could offer solutions that address not just the symptoms of these diseases, but their underlying causes, paving the way for transformative therapies in regenerative medicine.
As exosome-based therapies continue to attract investor attention, EVerZom’s approach is a compelling example of how cutting-edge biotechnology can deliver new hope to patients worldwide. With strategic funding, clinical validation on the horizon, and an expanding therapeutic portfolio, the company is poised for significant growth in the coming years.
If you need further assistance or have any corrections, please reach out to editor@thetimesmag.com.
